GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence
Combining a diabetes drug with cancer immunotherapy shows promise for improving survival in obese patients with certain cancers.
This review synthesizes mechanistic and real-world evidence for GLP-1 receptor agonists as adjuncts to immune checkpoint inhibitor therapy, showing they may reprogram the tumor microenvironment in obese patients. Observational data across multiple cancer types suggest improved survival and fewer adverse events with combination use.
What the study was
- Study design
- Narrative review
- Population
- Obese cancer patients receiving ICIs
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Future Oncology
Why it surfaced
Novel cross-domain review connecting GLP-1RAs with immuno-oncology. Clinically provocative hypothesis with real-world data support, though no prospective trial data yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.